Vyndamax (Tafamidis) Patent Expiration, LOE Window & CMS Spending

Vyndamax (Tafamidis) by Pfizer: FDA Orange Book core substance LOE 2035-08-31, 0 AB generics, $2.86B 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorPfizer
FDA Application & PathwayN212161 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2035-08-31
Last Listed Patent or Exclusivity Date2035-08-31
Orange Book Patents (*PED Extensions)3 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$2.86B
2024 Medicare Part D Spend$2.83B
2024 Medicaid Spend$27.0M
Reported Wholesale Price Change (CA SB 17)1 WAC filings (max 19.1% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.